Your browser doesn't support javascript.
loading
Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - A preliminary study.
Indian J Cancer ; 2013 Jan-Mar; 50(1): 46-51
Article in English | IMSEAR | ID: sea-147319
ABSTRACT

Introduction:

CD10 is a zinc-dependent peptidase (metalloproteinase). Stromal CD10 expression in breast cancer correlates with poor prognosis, oestrogen receptor negativity and higher grade. CD10 may be a potential target of new cancer therapies as it is involved in cleavage of doxorubicin.

Aim:

To evaluate the effect of neo-adjuvant anthracycline-based chemotherapy on status of stromal CD10 antigens in breast cancer. Materials and

Methods:

Patients with invasive breast cancer scheduled for anthracycline-based neo-adjuvant chemotherapy were included in the study. Tumor stromal CD10 expression was estimated before and after 3 cycles of chemotherapy, and change in its status was correlated with clinical response to chemotherapy.

Results:

16 out of the 29 patients had strong CD10 expression; in these 16 patients, 14 (87.5%) were hormone receptor negative, and 14 (87.5%) had HER-2/neu overexpression. Stromal CD10 expression remained same in 13 out of 29 cases (44.83%) after chemotherapy. There was a change in CD10 expression in the remaining 16 cases (55.17%); in 13 cases (44.83%) it decreased from its pre-chemotherapy status, while its expression increased in 3 cases (10.34%). In cases of complete and partial clinical response, there was no increase in CD10 expression. Where CD10 expression had increased after chemotherapy, there was either a minor response or no response to chemotherapy. In 13 cases where CD10 expression had decreased, 12 cases had a clinical response to chemotherapy.

Conclusions:

Strong CD10 expression correlates with hormone receptor negativity and HER-2/neu overexpression. Stromal CD10 expression in breast cancer is not static and changes with neo-adjuvant anthracycline-based chemotherapy. A stable or decrease in CD10 expression correlates with complete or partial clinical response, while an increase in CD10 expression appears to correlate with poor clinical response. A larger series is required to determine the clinical significance of these changes. As stromal CD10 expression and its change with chemotherapy may have a prognostic significance, they should be documented in breast cancer patients before and after chemotherapy.
Subject(s)

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Breast Neoplasms / Female / Humans / Neprilysin / Receptors, Estrogen / Gene Expression Regulation / Stromal Cells / Receptor, ErbB-2 / Anthracyclines / Adult Language: English Journal: Indian J Cancer Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Breast Neoplasms / Female / Humans / Neprilysin / Receptors, Estrogen / Gene Expression Regulation / Stromal Cells / Receptor, ErbB-2 / Anthracyclines / Adult Language: English Journal: Indian J Cancer Year: 2013 Type: Article